Clinical Trial

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
Protocol Amendment History 41 amendments
This ClinicalTrials.gov record has been amended 41 times since 2024-05-24; most recent amendment 2026-02-06.
Status change: Not Yet Recruiting → Recruiting 2024-07-30
Trial Details
NCT Number NCT06435429
Lead Sponsor Jazz Pharmaceuticals
Conditions Metastatic HER2-positive Breast Cancer
Enrollment 550 participants
Start Date 2024-08-13
Primary Completion 2028-04-28 (estimated)
Study Completion 2030-10-18 (estimated)
Updated on ClinicalTrials.gov 2026-02-10